ENDPOINTS

Pharma companies are weighing up how a drug’s IP location could impact tariffs

Over the past few months, several biopharma companies like GSK, Merck, Alnylam and BioMarin have said they are monitoring how the location of their drugs’ intellectual property could be relevant to President Donald Trump’s forthcoming ...

Jun 20, 2025 - 16:40
 0
Pharma companies are weighing up how a drug’s IP location could impact tariffs
Over the past few months, several biopharma companies like GSK, Merck, Alnylam and BioMarin have said they are monitoring how the location of their drugs’ intellectual property could be relevant to President Donald Trump’s forthcoming ...
Read More

Tags:

Previous Article

Island rivers carve passageways through coral reefs, maintaining ecosystem healt...

Next Article

From tech-first to climate-first: Why we must redefine how innovation is measured

Related Posts

Cullinan's deal for T cell engager from China; Kardigan buys late-stage heart drug

Cullinan's deal for T cell engager from China; Kardigan...

Jun 5, 2025  0

#ASCO25: Brain cancer cell therapies make early strides

#ASCO25: Brain cancer cell therapies make early strides

Jun 3, 2025  0

SV Health’s $269M dementia fund; Schrödinger lays off 7% of staff

SV Health’s $269M dementia fund; Schrödinger lays off 7...

May 20, 2025  0